Blog

Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2

In this paper, Killip et al., (Public Health England) have used RNAssist’s virusPHIX™ reagents to demonstrate SARS-CoV-2 inactivation. We were asked by the …

We’re attending the mRNA – Based Therapeutics Summit

We are delighted to attend the 2nd Annual mRNA-Based Therapeutics Summit 24th-26th January 2023 in Berlin. Following the successful development of vaccines …

QCMD to use RNAssist’s virusPHIX-P9™ Biomolecule Stabilization Technology in its SARS-CoV-2 antigen EQA scheme.

In a further development of the collaboration between QCMD and RNAssist, QCMD will use the universal biological sample stabilization virusPHIX-P9™ as the …

RNAssist stabilisation reagents published in the Biopreservation and Biobanking Journal (2019) for microbiome analysis

We are proud to have provided RNAssist reagents to the laboratory of Dr. Fay Betsou and Dr. Lorie Neuberger-Castillo at the Integrated …

RNAssist announces new manufacturing & supply agreement with Rapid Labs

RNAssist and Rapid Labs Agree on Manufacturing and Supply Agreement for genoPHIX™ and vivoPHIX™ Biomolecule Stabilisation, Tissue Fixation and Microbial Inactivation Technology. …

RNAssist Limited and QCMD Agree Collaboration for vivoPHIX™ Biomolecule Stabilization Technology

Cambridge and Glasgow, UK. 23rd January 2020 – RNAssist. (www.RNAssist.com) a UK company that has developed a universal biological sample stabilization, fixation …